Meyer May-Lucie, Hirsch Fred R, Bunn Paul A, Ujhazy Peter, Fredrickson David, Berg Christine D, Carbone David P, Halmos Balazs, Singh Harpreet, Borghaei Hossein, Ferris Andrea, Langer Corey, Dacic Sanja, Mok Tony S, Peters Solange, Johnson Bruce E
Hematology and Oncology Department, Tisch Cancer Institute at Mount Sinai, Icahn School of Medicine and Thoracic Oncology Center, New York, NY, United States.
Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, United States.
Oncologist. 2024 Dec 6;29(12):e1634-e1645. doi: 10.1093/oncolo/oyae169.
Lung cancer, the leading cause of cancer-related deaths globally, remains a pressing health issue despite significant medical advances. The New York Lung Cancer Foundation brought together experts from academia, the pharmaceutical and biotech industries as well as organizational leaders and patient advocates, to thoroughly examine the current state of lung cancer diagnosis, treatment, and research. The goal was to identify areas where our understanding is incomplete and to develop collaborative public health and scientific strategies to generate better patient outcomes, as highlighted in our "Calls to Action." The consortium prioritized 8 different calls to action. These include (1) develop strategies to cure more patients with early-stage lung cancer, (2) investigate carcinogenesis leading to lung cancers in patients without a history of smoking, (3) harness precision medicine for disease interception and prevention, (4) implement solutions to deliver prevention measures and effective therapies to individuals in under-resourced countries, (5) facilitate collaborations with industry to collect and share data and samples, (6) create and maintain open access to big data repositories, (7) develop new immunotherapeutic agents for lung cancer treatment and prevention, and (8) invest in research in both the academic and community settings. These calls to action provide guidance to representatives from academia, the pharmaceutical and biotech industries, organizational and regulatory leaders, and patient advocates to guide ongoing and planned initiatives.
肺癌是全球癌症相关死亡的主要原因，尽管医学取得了重大进展，但它仍然是一个紧迫的健康问题。纽约肺癌基金会召集了来自学术界、制药和生物技术行业的专家以及组织领导人与患者权益倡导者，对肺癌诊断、治疗和研究的现状进行了全面审视。目标是找出我们理解尚不完整的领域，并制定合作性的公共卫生和科学战略，以产生更好的患者治疗效果，正如我们的“行动呼吁”中所强调的那样。该联盟确定了8项不同的行动呼吁。这些包括：（1）制定策略治愈更多早期肺癌患者；（2）研究导致无吸烟史患者患肺癌的致癌过程；（3）利用精准医学进行疾病拦截和预防；（4）实施解决方案，向资源匮乏国家的个人提供预防措施和有效治疗；（5）促进与行业合作以收集和共享数据及样本；（6）创建并维护对大数据存储库的开放访问；（7）开发用于肺癌治疗和预防的新型免疫治疗药物；（8）在学术和社区环境中投资开展研究。这些行动呼吁为来自学术界、制药和生物技术行业、组织和监管领导人以及患者权益倡导者的代表提供指导，以指导正在进行和计划中的倡议。
